



the **ADBL** *report*

Issue #131, March 2023

An Official Accompaniment to the Alberta Drug Benefit List (ADBL) produced by Alberta Blue Cross

The Expert Committee on Drug Evaluation and Therapeutics (ECDET)

EXPERT COMMITTEE MEMBERS:

Fiona Clement, PhD, (Chair)
Micheal Guirguis, BScPharm, PhD (Vice-Chair)
Daniel Altman, BSc, MD, FRCPC
Caitlin A. Clarke, BScPhm, PharmD
Margaret Gray, BSP, FCSHP
Michael Kolber, BSc, MD, CCFP, MSc
Nicholas Myers, BSc, MB, BS, MRCPG (UK)

ALBERTA HEALTH LIAISON:

Andrea Nagle, BScPharm, LLB

ADMINISTRATIVE AND SCIENTIFIC SUPPORT:

Julia Chan, BSc (Pharm)
Amanda Chung, BSc (Pharm)
Sherry Dieleman, BSc (Pharm), MSc
Connie Lussier, BSP, MA

In this issue:

- *Brief Summary of Drug Review Activities*
- *Highlights of:*
 - ❖ *Products Originally Reviewed by CADTH*
 - ❖ *Interchangeable Drug Products Added*
 - ❖ *Drug Products Added*

Brief Summary of Drug Review Activities

The Expert Committee on Drug Evaluation and Therapeutics met on January 19, 2023. The Committee reviewed Manufacturer submissions for thirty-one (31) Drug Products for potential listing, or change in listing, on the ADBL. The Committee also considered information for a number of supplementary assessments of the coverage status of seventeen (17) Drug Products.

In addition to Drug Products reviewed by the Expert Committee, twenty (20) Drug Products and Devices underwent Expedited Review for listing on the ADBL effective March 1, 2023.

The following are highlights of recent changes to the ADBL and other topics of general interest. A complete list of changes, as well as the full ADBL may be accessed at <https://www.ab.bluecross.ca/dbl/publications.php>

Highlights of Products Originally Reviewed by the Canadian Agency for Drugs and Technologies in Health (CADTH)

The following Drug Product was reviewed by CADTH and the Expert Committee and added to the ADBL effective March 1, 2023:

- **RUZURGI* 10 mg tablet** (amifampridine) (MDK) via Special Authorization (SA)

A complete list of changes, as well as the full ADBL may be accessed at <https://www.ab.bluecross.ca/dbl/publications.php>.

Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).

Highlights of Interchangeable (IC) Drug Products Added

Addition of the following Entry IC Drug Products to the *ADBL* has resulted in the creation of New IC Groupings, effective March 1, 2023:

- **SANDOZ SITAGLIPTIN* 25 mg, 50 mg & 100 mg tablets** (sitagliptin) (SDZ) via Step Therapy/SA
- **APO-SITAGLIPTIN MALATE* 25 mg, 50 mg & 100 mg tablets** (sitagliptin) (APX) via Step Therapy/SA
- **AURO-HYDROCORTISONE 10 mg & 20 mg tablets** (hydrocortisone) (AUR)

Highlights of Drug Products Added

The following Drug Product was reviewed by the Expert Committee and added to the *ADBL* effective March 1, 2023:

- **TEVA-PREDNISONE 50 mg tablet** (prednisone) (TEV)

A complete list of changes, as well as the full *ADBL* may be accessed at <https://www.ab.bluecross.ca/dbl/publications.html>.

*Please refer to the current *ADBL* for explanations of coverage, including a listing of coverage criteria (where applicable).*